Results 101 to 110 of about 135,991 (315)
GMS German Medical Science, 2012 In 2007 the Association of Research-Based Pharmaceutical Companies (vfa) published recommendations to improve the quality and transparency of non-interventional studies. These recommendations include quality assurance measures, in particular with respect
Thorsten Ruppert +2 more
doaj
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet +17 more
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
British Journal of Clinical Pharmacology, EarlyView.Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Long-term cost-effectiveness of pharmacist-managed hypertension care in China
BMC Health Services ResearchBackground Hypertension is one of the main causes of cardiovascular and kidney diseases in China. However, the rate of effective blood pressure control remains low.
Jingxuan Wei +6 more
doaj +1 more source
Frontiers in PharmacologyObjectivesThe charging policy of pharmacy intravenous admixture service (PIVAS) is not merely a minor “billing issue” confined to individual hospitals, but rather a critical component that impacts the safety, efficiency, equity, and long-term ...
Jie Cao +5 more
doaj +1 more source
Health-care Reform in Slovakia [PDF]
Gesundheitsreform, Slowakei, Health care reform ...
Anton Marcincin +2 more
core
Stagnation in the Drug Development Process: Are Patents the Problem? [PDF]
, 2007 The rate of new drug development has stagnated, in spite of large increases in both private and public sector spending on biomedical research. The flip side of slower progress is higher drug costs.
Dean Baker
core
Developing medication independence: The experience of UK teenagers
British Journal of Clinical Pharmacology, EarlyView.Aims There is a progression through childhood from being provided medications by caregivers to having to take responsibility for medications yourself, but little is known about when the transition of adolescents managing medicines begins. The aim of this study was to obtain a cross‐sectional sample of UK adolescents and when they become independent ...
Holly Hutchins +5 more
wiley +1 more source
Педиатрическая фармакология, 2019 Background. Currently, scleroderma is a rather rare disease, including among children. Despite the growing interest of investigators in this pathology, the problem of diagnosing oesophageal affection in various forms of systemic sclerosis remains under ...
Marina Ju. Stepanyan +3 more
doaj +1 more source